00:28 , Aug 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Three host gene targets for malaria

DISEASE CATEGORY: Infectious INDICATION: Malaria A team from Duke University identified host targets whose inhibition could prevent malaria infection. A human liver-cell based RNAi screen of 6,951 druggable genes identified 14 that promoted the liver...
04:36 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Enhancing malaria prevention with a non-neutralizing mAb

DISEASE CATEGORY: Infectious disease INDICATION: Malaria A non-neutralizing mAb against P. falciparum Rh5, which mediates red blood cell invasion, could improve the efficacy of vaccines based on neutralizing antibodies against the antigen or other malarial...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
20:00 , Apr 23, 2019 |  BC Extra  |  Company News

Pilot program for GSK's malaria vaccine starts in Malawi

WHO launched a planned pilot program of GSK's malaria vaccine RTS,S in Malawi on Tuesday with the goal of informing the organization's policy recommendations for broader use of the vaccine. The organization will also roll...
21:49 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Microbial lysine-tRNA ligase inhibitor for malaria and Cryptosporidium

DISEASE CATEGORY: Infectious disease INDICATION: Malaria; Cryptosporidium In vitro , cell culture and mouse studies identified a chromene carboxamide-based inhibitor of P. falciparum lysine-tRNA ligase and Cryptosporidium lysine-tRNA ligase that could help treat malaria and...
23:22 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria Cell culture, patient sample and mouse studies identified a bitriazine-based compound that could help treat malaria. Chemical synthesis and testing of bitriazine analogs in human erythrocyte-based assays of Plasmodium falciparum growth identified a...
21:37 , Feb 14, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January. Therapeutic targets are defined as any protein, gene or other molecule...
00:06 , Jan 23, 2019 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays An assay for detecting P. falciparum PSSP17 in saliva could help rapidly diagnose clinical and subclinical P. falciparum infection at the point of care. The assay comprises mixing saliva samples with two...
22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria In vitro and cell culture studies identified two P. falciparum PK9 inhibitors that could help treat malaria. Screening of a kinase inhibitor library in HEK cells expressing P. falciparum PK9, in vitro binding...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...